Vaccines versus immunotherapy: Overview of approaches in deciding between options

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New Engl J Med 1997; 336:1855-9; PMID:9197213; http://dx.doi.org/10.1056/NEJM199706263362602
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
   PubMed Web of Science ®Google Scholar
• Chung CH, Bagheri A, D’Souza G. Epidemiology of oral human papillomavirus infection. Oral Oncol 2014; 50:364-9; PMID:24080455; http://dx.doi.org/10.1016/j.oraloncology.2013.09.003
   PubMed Web of Science ®Google Scholar
• Ward S, Dalgleish A. Therapeutic cancer vaccines. Vaccine 2007; 25 Suppl 2:B1-3; PMID:17681649; http://dx.doi.org/10.1016/j.vaccine.2007.06.042
   PubMedGoogle Scholar
• Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998; 52:520-9; PMID:9894850; http://dx.doi.org/10.1111/j.1399-0039.1998.tb03082.x
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11:4469-78; PMID:15958632; http://dx.doi.org/10.1158/1078-0432.CCR-04-2337
   PubMed Web of Science ®Google Scholar
• Browning M, Dalgleish AG. Introduction and historical perspective. In: Sikora K, Dalgleish AG, Browning M, eds. Tumour Immunology. London: Cambridge University Press, 1996.
   Google Scholar
• Sapre N, Corcoran NM. Modulating the immune response to Bacillus Calmette-Guerin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer? BJU Int 2013; 112:852-3; PMID:24028766; http://dx.doi.org/10.1111/bju.12261
   PubMed Web of Science ®Google Scholar
• Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68:158-63; discussion 63-4; PMID:10483463
   PubMed Web of Science ®Google Scholar
• Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008; 26:4984-90; PMID:18625281; http://dx.doi.org/10.1016/j.vaccine.2008.06.092
   PubMed Web of Science ®Google Scholar
• Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236:438-48; discussion 48-9; PMID:12368672; http://dx.doi.org/10.1097/00000658-200210000-00006
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL, Morton DL. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 1999; 85:2160-9; PMID:10326694; http://dx.doi.org/10.1002/(SICI)1097-0142(19990515)85:10%3c2160::AID-CNCR10%3e3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190:617-27; PMID:10477547; http://dx.doi.org/10.1084/jem.190.5.617
   PubMed Web of Science ®Google Scholar
• Cananzi FC, Mudan S, Dunne M, Belonwu N, Dalgleish AG. Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Human vaccines Immunother 2013; 9(11):2427-33; PMID:23863507; http://dx.doi.org/10.4161/hv.25618
   PubMed Web of Science ®Google Scholar
• Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2012; 61:535-47; PMID:22002242; http://dx.doi.org/10.1007/s00262-011-1121-4
   PubMed Web of Science ®Google Scholar
• Xu LJ, Wang YY, Zheng XD, Gui XD, Tao LF, Wei HM. Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice. Cellular Mol Immunol 2009; 6:67-72; PMID:19254482; http://dx.doi.org/10.1038/cmi.2009.9
   PubMed Web of Science ®Google Scholar
• Le Bert N, Chain BM, Rook G, Noursadeghi M. DC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathway. PloS One 2011; 6:e18346; PMID:21483768; http://dx.doi.org/10.1371/journal.pone.0018346
   PubMedGoogle Scholar
• Basu J, Shin DM, Jo EK. Mycobacterial signaling through toll-like receptors. Front Cell Infect Microbiol 2012; 2:145; PMID:23189273; http://dx.doi.org/10.3389/fcimb.2012.00145
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 2013; 62:1041-52; PMID:23591981; http://dx.doi.org/10.1007/s00262-013-1415-9
   PubMed Web of Science ®Google Scholar
• Hsueh EC ER, Foshag LJ, Olila DW, Gammon G, O’Day SJ, Boasber PD, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20:4549-54; PMID:12454111; http://dx.doi.org/10.1200/JCO.2002.01.151
   PubMed Web of Science ®Google Scholar
• Qiu B, Zhang D, Wang C, Tao J, Tie X, Qiao Y, Xu K, Wang Y, Wu A. IL-10 and TGF-beta2 are overexpressed in tumor spheres cultured from human gliomas. Mol Biol Rep 2011; 38:3585-91; PMID:21088899; http://dx.doi.org/10.1007/s11033-010-0469-4
   PubMed Web of Science ®Google Scholar
• Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 2008; 632:159-74; PMID:19025121
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Investigat 2007; 36:25-46; PMID:17190648; http://dx.doi.org/10.1080/08820130600991893
   PubMed Web of Science ®Google Scholar
• Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy? Brit J Cancer 2009; 100:1697-703; PMID:19384299; http://dx.doi.org/10.1038/sj.bjc.6605040
   PubMed Web of Science ®Google Scholar
• Martin F, Apetoh L, Ghiringhelli F. Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy-Uk 2012; 4:43-57; http://dx.doi.org/10.2217/imt.11.154
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol, Immunother : CII 2011; 60:1161-71; PMID:21626032; http://dx.doi.org/10.1007/s00262-011-1012-8
   PubMedGoogle Scholar
• Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003; 13:389-93; PMID:12883365; http://dx.doi.org/10.1097/00008390-200308000-00008
   PubMed Web of Science ®Google Scholar
• Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012; 32:5363-9; PMID:23225438
   PubMed Web of Science ®Google Scholar
• Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9:900-9; PMID:19336265; http://dx.doi.org/10.1016/j.intimp.2009.03.015
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85:473-83; http://dx.doi.org/10.1054/bjoc.2001.1943
   PubMed Web of Science ®Google Scholar
• Dalgleish AG, O’Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res 2006; 130:1-38; PMID:16610701; http://dx.doi.org/10.1007/0-387-26283-0_1
   PubMedGoogle Scholar
• Lee CS, McNamara D, O’Morain CA. Aspirin as a chemoprevention agent for colorectal cancer. Curr Drug Metab 2012; 13:1313-22; PMID:22493984; http://dx.doi.org/10.2174/138920012803341384
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, Skaar T, De Petris G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009; 182:216-24; http://dx.doi.org/10.4049/jimmunol.182.1.216
   PubMed Web of Science ®Google Scholar
• Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006; 177:2391-402; http://dx.doi.org/10.4049/jimmunol.177.4.2391
   PubMed Web of Science ®Google Scholar
• Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol, Immunother : CII 2011; 60:931-42; PMID:21431419; http://dx.doi.org/10.1007/s00262-011-1002-x
   PubMed Web of Science ®Google Scholar
• Dalgleish A, Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol 2010; 6:1479-84; PMID:20919830; http://dx.doi.org/10.2217/fon.10.105
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955-61; PMID:14997189; http://dx.doi.org/10.1038/sj.bjc.6601579
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168:4914-9; PMID:11994441; http://dx.doi.org/10.4049/jimmunol.168.10.4914
   PubMed Web of Science ®Google Scholar
• Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012; 18:1426-34; PMID:22241792; http://dx.doi.org/10.1158/1078-0432.CCR-11-1221
   PubMed Web of Science ®Google Scholar
• Lacy MQ, McCurdy AR. Pomalidomide. Blood 2013; 122:2305-9; PMID:23974193; http://dx.doi.org/10.1182/blood-2013-05-484782
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-22; PMID:15057291; http://dx.doi.org/10.1038/nrc1323
   PubMed Web of Science ®Google Scholar
• Liu WM, Dalgleish AG. The potential beneficial effects of drugs on the immune response to vaccination. Semin Oncol 2012; 39:340-7; PMID:22595056; http://dx.doi.org/10.1053/j.seminoncol.2012.02.012
   PubMed Web of Science ®Google Scholar
• Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003; 24:58-61; PMID:12547500; http://dx.doi.org/10.1016/S1471-4906(02)00029-7
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl J Med 2011; 364:2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008; 105:20410-5; PMID:19074257; http://dx.doi.org/10.1073/pnas.0810114105
   PubMed Web of Science ®Google Scholar
• Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12:864-72; PMID:17673617; http://dx.doi.org/10.1634/theoncologist.12-7-864
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63:8408-13; PMID:14679003
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008; 14:5284-91; PMID:18698048; http://dx.doi.org/10.1158/1078-0432.CCR-07-5162
   PubMed Web of Science ®Google Scholar
• Thariat J, Boudabous M. [The abscopal effect, synergy between immunotherapy and radiotherapy]. Bull Du Cancer 2013; 100:1071; PMID:24409482
   PubMed Web of Science ®Google Scholar
• Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012; 72:3439-44; PMID:22761338; http://dx.doi.org/10.1158/0008-5472.CAN-11-3912
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
   PubMed Web of Science ®Google Scholar
• Nars MS, Kaneno R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 2013; 132:2471-8; PMID:22927096; http://dx.doi.org/10.1002/ijc.27801
   PubMed Web of Science ®Google Scholar
• Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000; 82:1009-12; PMID:10737381; http://dx.doi.org/10.1054/bjoc.1999.1034
   PubMed Web of Science ®Google Scholar
• Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG, Kumar D. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 2006; 94:1412-9; PMID:16641913; http://dx.doi.org/10.1038/sj.bjc.6603104
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar